Items where authors include "Seymour, M.T."
Article
Williams, C.J.M. orcid.org/0000-0002-1574-653X, Elliott, F. orcid.org/0000-0002-3239-6914, Sapanara, N. orcid.org/0009-0005-0994-837X et al. (51 more authors) (2023) Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer. Clinical Cancer Research, 29 (20). pp. 4153-4165. ISSN 1078-0432
Williams, C.J.M. orcid.org/0000-0002-1574-653X, Elliott, F. orcid.org/0000-0002-3239-6914, Sapanara, N. orcid.org/0009-0005-0994-837X et al. (51 more authors) (2023) Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer. Clinical Cancer Research, 29 (20). pp. 4153-4165. ISSN 1078-0432
Williams, C.J.M. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Elliott, F. et al. (24 more authors) (2021) Artificial Intelligence–Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 27 (12). pp. 3422-3431. ISSN 1078-0432
Ward, S.E. orcid.org/0000-0002-3344-0913, Kaltenthaler, E. orcid.org/0000-0002-6185-8321, Cowan, J. et al. (3 more authors) (2006) The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. British Journal of Cancer, 95 (1). pp. 27-34. ISSN 0007-0920
Proceedings Paper
Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.